* Sales -5%, adj. EBITA +25% vs. ABGSCe, 0% org. growth * '25e-'27e adj.
Redeye views Genovis’ Q3 as softer than anticipated.
RaySearch delivers incredibly strong results with record sales, a 96% gross margin, and an EBIT marg...
Redeye provides an initial comment on the Q3 2025 report from Catella.
Redeye updates on W5 post Q3-results which saw softer-than-expected topline while a strong gross mar...
Nanexa’s Q3 report underscores a pivotal moment for the company.
* Sales in line, EBIT adj. EUR +0.5m vs. ABGSCe * Orders -18% vs.
* Orders +8%, sales +1%, adj. EBITA -9% vs. ABGSCe * Sees recovery amongst customers, Enedo profitab...
Redeye comments on Fable Media’s updated full-year forecast.
Redeye provides an update following Optomed’s Q3 2025 report.
Redeye adjusts its estimates and fair value range following Arise’s Q3 report.
CapMan posted a strong set of Q3 2025 numbers, with profitability coming in above our expectation.
Kontigo Care delivered Q3 results broadly in line with our forecasts, with stable MRR and controlled...
Redeye retains its positive view of Transtema, despite a soft Q3 report, which shows further decline...
Redeye comments briefly on the Q3 report and other recent news.
* Uneventful Q3, but big financing news after the quarter * Equity raise at SEK 19/share, 5pp less d...
* We trim EBIT by 4-3% on slightly lower margins * Strong growth continues, with impressive margin r...
Rekord i både omsättning och vinst i säsongsmässigt starkt kvartal.
* We raise our long-term EBIT estimates on better growth * Short-term margins sacrificed, but LT gro...
Administer’s Q3 was soft, with lower net sales weighing on profitability.
